D. E. Shaw & Co., Inc. Allovir, Inc. Transaction History
D. E. Shaw & Co., Inc.
- $98.6 Billion
- Q2 2024
A detailed history of D. E. Shaw & Co., Inc. transactions in Allovir, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 475,585 shares of ALVR stock, worth $380,468. This represents 0.0% of its overall portfolio holdings.
Number of Shares
475,585
Previous 869,862
45.33%
Holding current value
$380,468
Previous $661,000
48.26%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding ALVR
# of Institutions
75Shares Held
46.5MCall Options Held
201KPut Options Held
3.1K-
Eco R1 Capital, LLC San Francisco, CA11.3MShares$9.04 Million0.29% of portfolio
-
Octagon Capital Advisors LP New York, NY9.8MShares$7.84 Million1.63% of portfolio
-
Artal Group S.A. Luxembourg, N46.6MShares$5.28 Million0.3% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.3MShares$2.64 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.65MShares$2.12 Million0.0% of portfolio
About Allovir, Inc.
- Ticker ALVR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 93,063,400
- Market Cap $74.5M
- Description
- Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, ...